Item 7.01. Regulation FD Disclosure.

On January 10, 2023, Jasper Therapeutics, Inc. (the "Company") issued a press release announcing that, as part of an overall portfolio prioritization, the Company will focus primarily on the development of its lead product candidate, briquilimab (formerly known as JSP191), in chronic diseases and stem cell transplant for rare diseases. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The Company is also furnishing an updated corporate presentation, attached as Exhibit 99.2 to this Current Report on Form 8-K (the "Corporate Presentation"), which the Company intends to post on the Company's website. The Corporate Presentation is current as of January 10, 2023, and the Company disclaims any obligation to update this material in the future.

The information in this Item 7.01, including the press release attached hereto as Exhibit 99.1 and the Corporate Presentation attached hereto as Exhibit 99.2, is being furnished under Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.




Exhibit
No.       Description
 99.1       Press Release, dated January 10, 2023.
 99.2       Corporate Presentation, dated January 2023.
  104     Cover Page Interactive Data File, formatted in Inline Extensible
          Business Reporting Language (iXBRL).




                                       1

© Edgar Online, source Glimpses